AT-007 in Adult Subjects With Classic Galactosemia (CG)

Classic Galactosemia Clinical Trial

Official title: An Open-Label Study to Evaluate the Long-Term Safety and Pharmacodynamic Efficacy of AT-007 in Adult Subjects With Classic Galactosemia (CG)

Status Active, not recruiting

Clinical Trial Summary

This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG who previously participated in Study AT-007-1001 Part D and/or Part D Extension. The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects with CG will also be evaluated.

Clinical Trial Description

Primary: - To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with Classic Galactosemia (CG) Secondary: - To evaluate the long-term inhibition of galactitol, a biomarker of aldose reductase (AR) activity, induced by 12-month oral administration of AT-007 to adult subjects with CG - To evaluate the pharmacokinetic (PK) parameters of 12-month oral administration of AT-007 in adult subjects with CG Exploratory: - To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG - To evaluate the burden of illness (BOI) of adult subjects with CG - To evaluate quality of life (QOL) measures of adult subjects with CG - To evaluate the effect of 12-month oral administration of AT-007 on the BOI and QOL of adult subjects with CG ;

Related Conditions & MeSH terms

• Classic Galactosemia
• Galactosemias

• NCT number: NCT05418829
• Study type: Interventional
• Source: Applied Therapeutics, Inc.
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 1, 2021
• Completion date: December 2022